Toggle light / dark theme

“After demonstrating that cultured meat can reach cost parity faster than the market anticipated, this production facility is the real game-changer,” said Yaakov Nahmias, Future Meat Technologies founder and chief scientific officer, in a press release. “This facility demonstrates our proprietary media rejuvenation technology in scale, allowing us to reach production densities 10-times higher than the industrial standard.”

Cultured meat is made by extracting cells from animal tissue and giving them nutrients, oxygen, and moisture while keeping them at the same temperature they’d be at inside an animal’s body. The cells divide and multiply then start to mature, with muscle cells joining to create muscle fibers and fat cells producing lipids. The resulting nuggets of meat can be used to make processed products like burgers or sausages. Structured cuts of meat with blood vessels and connective tissue, like steak or chicken breast, require scaffolds, and researchers are creating these with biomaterials, like cellulose from plants. Companies are working on several varieties of more elaborate cultured products, from bacon to salmon.

As reported by Bloomberg, Future Meat aims to start offering its products in US restaurants by the end of next year—but must get approval from the FDA first. On top of that approval, public opinion is another hurdle the company and its competitors will need to clear before they see widespread success; for every person who’s opposed to factory farming, there’s a person who’s squeamish about the idea of meat grown in a bioreactor, despite the avian (or bovine, or porcine) lives being spared. Getting these consumers to view cultured meat favorably will be a matter of education, taste/texture as compared to the ‘real thing,’ and cost competitiveness.

Thanks Jeff


Jeff Bezos, the world richest man is investing in anti-ageing technology that could extend the average human lifespan by up to 50 years, WITHIN NIGERIA learnt.

It was also learnt that Jeff Bezos is one of the several billionaire investors in Altos Labs, a Silicon Valley tech firm working on experimental – and potentially dangerous – new life extension technologies.

The new company has hired dozens of experts from top universities to research how cells age and how to reverse that process.

This is an excerpt I made from a conversation between Sergey Young and David Sinclair. Along it, they share their impressions as to how much Longevity science have progressed during the last few years.

The link to the entire conversation and the Q&As from the audience that was watching the webinar is in the description of the video.

𝗛𝗲 𝗮𝗴𝗿𝗲𝗴𝗮𝗱𝗼 𝘀𝘂𝗯𝘁𝗶́𝘁𝘂𝗹𝗼𝘀 𝗲𝗻 𝗘𝘀𝗽𝗮𝗻̃𝗼𝗹 🙂


Excerpt from an interview made by Sergey Young to David Sinclair on may 29 2021.

To watch the entire interview clic here: https://youtu.be/JCnXRJsgnlI

Dr. The book launch will happen on September 4th, at 3 p.m. (Pacific Time) in Book Passage Ferry Building Store in San Francisco, California!
Please come to have an in-person chat with Dr. Katcher.

Dr. Harold Katcher is one of the discoverers of the human breast cancer gene (BRCA1), and has thousands of citations in the scientific literature, with publications ranging from protein structure to bacteriology, biotechnology, bioinformatics and biochemistry. He was the Academic Director for Natural Sciences for the Asian Division of the University of Maryland Global Campus, and nowadays is Chief Scientific Officer at Yuvan Research Inc., which is working on the development of rejuvenation treatments.

https://www.bookpassage.com/event/harold-katcher-illusion-kn…ding-store.
https://www.ntzplural.com/harold-katcher-launches-book.
https://www.facebook.com/events/553354852782737?ref=newsfeed.

#haroldkatcher #sanfrancisco #california #booklaunch #biotechnology #rejuvenation #aging.

Created with the voices from LOVO @ www.lovo.ai.

The late 21st century belongs to Superhumans. Technological progress in the field of medicine through gene editing tools like CRISPR is going to revolutionize what it means to be human. The age of Superhumans is portrayed in many science fiction movies, but for the first time in our species history, radically altering our genome is going to be possible through the methods and tools of science.

The gene-editing tool CRISPR, short for clustered regularly interspaced short palindromic repeats, could help us to reprogram life. It gives scientists more power and precision than they have ever had to alter human DNA.

Genetic engineering holds great promise for the future of humanity. A growing number of scientists including David Sinclair believe that we will soon be able to engineer and change our genes in a way that will help us live longer and healthier lives.

But how much should we really tinker with our own nature? What is the moral responsibility of scientists and humans towards future generations?

With technological advances in molecular biology like CRISPR that allow for specific gene editing approaches, many scientists argue that there are strong potential benefits as well as risks to human genetic engineering.
David Sinclair is a geneticist at Harvard Medical School. He believes it’s possible to unlock the fountain of youth.

The potential uses of such gene editing techniques could range from the treatment of disease to the enhancement of beauty and intelligence.

Brent Nally interviews Dr Katcher about E5 plasma filtering. “What’s the purpose of anything if you’re gonna die?” E5 human trials perhaps by the end of 2022. All treated rats so far are still alive. “The question is how many times can we do this?” So far with rats it’s 3 times. He has not given out the specific E5 formula. Right now there is another party attempting to repeat his rat experiments.


Harold earned his PhD in Biology, is Chief Science Officer of Yuvan Research and is one of the discoverers of the breast cancer gene (BRCA1). Harold describes in his book, The Illusion of Knowledge, his personal story and journey developing E5 which may be extremely promising for the field of rejuvenation/biological age reversal. Read this May2020paper.

Sign up for free: https://LongevityPlan.com https://Twitter.com/BrentNally https://Patreon.com/BrentNally https://Linkedin.com/in/BrentNally https://Instagram.com/Brent.Nally https://Facebook.com/Brent.Nally https://Reddit.com/user/BrentNally Discord Brent Nally#0616 TikTok @brentnally Telegram https://t.me/brentnally https://medium.com/@BrentNally https://BrentNally.tumblr.com Snapchat BrentNally.

- My mission is to solve the human aging problem ASAP.

- I NEED YOUR SUPPORT:

In order to find a way to trick the body into making new B cells, the researchers probed one of the ways that the body naturally replenishes its supply. Patients undergoing treatment for multiple sclerosis had their MBC stock depleted, at which point their body rapidly started to produce new B cells.

The team identified the specific hormones that shut B cell production down again once stores were replenished, and realized that deactivating the hormone results in the body producing extra B cells left and right. And going forward, they hope to turn that hormonal trick into a new rejuvenating treatment for the elderly and immunocompromised.

“We found specific hormonal signals produced by the old B cells, the memory cells, that inhibit the bone marrow from producing new B cells,” Melamed told The Jerusalem Post. “This is a huge discovery. It is like finding a needle in a haystack.”

The Human Cell Atlas is the world’s largest, growing single-cell reference atlas. It contains references of millions of cells across tissues, organs and developmental stages. These references help physicians to understand the influences of aging, environment and disease on a cell—and ultimately diagnose and treat patients better. Yet, reference atlases do not come without challenges. Single-cell datasets may contain measurement errors (batch effect), the global availability of computational resources is limited and the sharing of raw data is often legally restricted.

Researchers from Helmholtz Zentrum München and the Technical University of Munich (TUM) developed a novel called “scArches,” short for single-cell architecture surgery. The biggest advantage: “Instead of sharing raw data between clinics or research centers, the algorithm uses transfer learning to compare new from single-cell genomics with existing references and thus preserves privacy and anonymity. This also makes annotating and interpreting of new data sets very easy and democratizes the usage of single-cell reference atlases dramatically,” says Mohammad Lotfollahi, the leading scientist of the algorithm.